(trimethylsilyl)aminolithium | 52057-93-9

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (trimethylsilyl)aminolithium
• 英文别名: LiNTMS(tBu)；lithium (trimethylsilyl)amide；Lithium(trimethylsilyl)amide；lithium;trimethylsilylazanide
• CAS: 52057-93-9
• 化学式: C₃H₁₀NSi*Li
• 分子量: 95.1456
• InChiKey: HMRCZKQIOFZACX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.12
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (trimethylsilyl)aminolithium 、 叔丁基二甲基氯硅烷 以35%的产率得到N,N-trimethylsilyl-tert-butyldimethylsilylamine
  参考文献：
  名称：

  13C, 15N and 29Si nuclear magnetic resonance studies of some aminosilanes and aminodisilanes

  摘要：

  DOI：

  10.1016/0584-8539(89)80188-6
• 作为产物：
  描述：

  N-叔丁基三甲基硅基胺 在 正丁基锂 作用下， 以 正己烷 、 正戊烷 为溶剂， 以68%的产率得到(trimethylsilyl)aminolithium
  参考文献：
  名称：

  阳离子钒双酰亚胺配合物催化的炔烃Z选择性半氢化反应

  摘要：

  早期金属达到H：在H 2的1个大气压下，钒络合物1（PFTB =全氟叔丁醇）催化将炔烃半 氢化为Z烯烃。合成的和DFT研究，在用H组合2 / d 2和NMR实验，表明ħ 2由1,2-加成至活化的1。将炔烃插入A的VH键后，烯基配体的1,2-α-NH-消除会生成烯烃和1的产物。

  DOI：

  10.1002/anie.201007876
• 作为试剂：
  描述：

  1,4-苯二硼酸 在 四(三苯基膦)钯 (trimethylsilyl)aminolithium 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis, DNA Affinity, and Antiprotozoal Activity of Linear Dications:  Terphenyl Diamidines and Analogues

  摘要：

  Diamidines 10a-g and 18a, b were obtained from dinitriles 9a-g and 15a, b by treatment with lithium trimethylsilylamide or upon hydrogenation of bis-O-acetoxyamidoximes. Dinitriles 9a-g were prepared via Suzuki reactions between arylboronic acids and arylnitriles. Potential prodrugs 12a-f and 17 were prepared via methylation of the diamidoximes 11a-f and 16a. Significant DNA affinities for rigid-rod molecules were observed. Compounds 10a, 10b, 10d, 18a, and 18b show IC50 values of 5 nM or less against Trypanosoma brucei rhodesiense ( T. b. r.) and 10a, 10b, 10e, 18a, and 18b gave similar ones against Plasmodium falciparum ( P. f.). The dications, 10a, 10d, 10f, and 10g are more active than furamidine in vivo. The prodrugs are only moderately effective on oral administration. Mouse liver microsome bioconversion of the methamidoxime prodrugs is significantly reduced from that of pafuramidine and suggests that the in vivo efficacy of these prodrugs is, in part, due to poor bioconversion.

  DOI：

  10.1021/jm060470p

文献信息

• Preparation and purification of 4-(indazol-3-yl) phenols
  申请人：Considine Leo John

  公开号：US20060111574A1

  公开（公告）日：2006-05-25

  The present invention concerns processes for the production and purification of compounds of the formula: where R 1 -R 10 are as defined in the specification. Preferred processes of the invention utilize a lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and a R 1 —X alkylating agent where X is as described in the specification. An alcohol preferably is added to the product solution is used to promote crystallization of the desired product.

  本发明涉及制备和纯化以下化合物的过程：式中R1-R10如规范中所定义。本发明的优选过程利用锂双(三甲基硅基)胺、锂双环己基胺或钾双(三甲基硅基)胺碱和R1-X烷基化剂，其中X如规范中所述。最好添加醇到产物溶液中，以促进所需产物的结晶。
• Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
  申请人：——

  公开号：US20030195352A1

  公开（公告）日：2003-10-16

  This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.

  本发明涉及新型苯并呋喃和二氢苯并呋喃化合物，含有这些化合物的药物组合物以及使用这些组合物治疗β-3肾上腺素能受体介导的疾病的方法。
• Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
  申请人：——

  公开号：US20030078258A1

  公开（公告）日：2003-04-24

  This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.

  本发明涉及一种新型的二取代氨基甲基色酮衍生物，其在治疗β-3受体介导的疾病方面具有用途。
• Antibacterial agents
  申请人：Boyer Earl Frederick

  公开号：US20050288273A1

  公开（公告）日：2005-12-29

  Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

  本文披露了I式化合物及其制备方法。此外，还披露了制备具有生物活性的I式化合物的方法，以及包含I式化合物的药学上可接受的组合物的方法。本文所披露的I式化合物可以用于多种应用，包括用作抗菌剂。
• Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
  申请人：Zhang Chenzhi

  公开号：US20050014805A1

  公开（公告）日：2005-01-20

  This invention relates to novel heterocyclic compounds, compositions, and methods for treating or preventing obesity and obesity-related diseases.

  本发明涉及新的杂环化合物、组合物和用于治疗或预防肥胖和肥胖相关疾病的方法。